



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Translational Medicine

ESPS Manuscript NO: 7166

Title: Epithelial Ovarian Cancer – An Overview

Reviewer code: 00742250

Science editor: Song, Xiu-Xia

Date sent for review: 2013-11-10 20:57

Date reviewed: 2013-11-12 11:25

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The review article is concise and seems poor in contents because some important reports are not included in this text. The authors should discuss on pathogenesis of epithelial ovarian cancer according to hypothesis of Kurman's group. They also should describe loss of ARID1A concerning clear cell carcinogenesis. In addition, in treatment section, the authors should refer to GOG-ICON5 trial, NOVEL trial (from Japan study, dose dense weekly TC), and SCOTROC trial. The article of Ref No. 45 is inappropriate in the text. The authors should mention OCEAN trial and AURELIA trial in the treatment of recurrent epithelial ovarian cancer.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Translational Medicine

ESPS Manuscript NO: 7166

Title: Epithelial Ovarian Cancer – An Overview

Reviewer code: 00742249

Science editor: Song, Xiu-Xia

Date sent for review: 2013-11-10 20:57

Date reviewed: 2013-11-12 19:27

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Comments: The authors concisely reviewed a molecular biology of oncogenesis, histopathology, and therapeutics of epithelial ovarian cancer. This manuscript provides useful information to the medical students, clinicians, and researchers in this field, therefore, is acceptable for publication in World Journal of Translational Medicine. That is all.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Translational Medicine

ESPS Manuscript NO: 7166

Title: Epithelial Ovarian Cancer – An Overview

Reviewer code: 00742268

Science editor: Song, Xiu-Xia

Date sent for review: 2013-11-10 20:57

Date reviewed: 2013-11-20 21:32

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

General comment: A scholastic review that provides only a brief overview on the current state of ovarian cancer research. In detail: chapter genetic anomalies and syndromes needs to be expanded to fulfill criteria for an excellent review article and should include following research topics expression profiling, genomic imbalances, ovarian stem cells, micro RNAs, next generation sequencing, and epigenetics. One of the major publications in the field of research has to be discussed: Integrated genomic analyses of ovarian carcinoma. Cancer Genome Atlas Research Network. Nature. 2011 Jun 29;474(7353):609-15



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Translational Medicine

ESPS Manuscript NO: 7166

Title: Epithelial Ovarian Cancer – An Overview

Reviewer code: 00742220

Science editor: Song, Xiu-Xia

Date sent for review: 2013-11-10 20:57

Date reviewed: 2013-11-27 16:18

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

A paper of interest in its field. It's updated and well written. However it needs major revisions. Treatment section: The term of optimal cytoreduction should be specified better. In fact the limit of 1 cm is not still universally recognized as the best. In stage III and IV cancer is partially explained the benefit of debulking surgery declaring the necessity of any grossly visible tumor (in apparent opposition to the definition of optimal cytoreduction given before). Moreover the benefits of cytoreductive surgery have been largely demonstrated by many authors (the most recent publications Bristow, Ansaloni on WJOG 2013). The role of laparoscopy in staging should be explained. Lastly the role of neoadjuvant chemotherapy should be discussed as it is of pivotal role in many situations.